Assessing the Effects of Increased Mitochondrial Function Exercise Training on Muscle Performance (Rejuvenate2)

University of Exeter

Status: Terminated

Conditions: Impaired Mitochondrial Function, Muscle Performance

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Acipimox

Study type: Interventional

Funder types: Other

Identifiers

NCT03325491

1617/024

Details and patient eligibility

About

As people grow older skeletal muscle gradually becomes smaller and weaker, causing reduced mobility and quality of life. To understand and reverse this negative process investigators need to find new ways of improving the ability of muscle to perform physical activity. There is some evidence that supplements may improve how the mitochondria work, and investigators want to explore this idea in more detail. This is possible by measuring how the muscles work and respond to exercise before and after taking the supplement alongside an aerobic (i.e. cycling) and resistance (i.e. weight lifting) exercise programme. This will give us the basic information investigators would need to see if this is a useful idea.

Enrollment: 2 patients

Sex: Male

Ages: 65 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male
• Age between 65-75 years
• Body mass index between 19-29
• No active cardiovascular or metabolic disease
• No active respiratory disease
• No current musculoskeletal injuries
• A sedentary lifestyle (i.e. does not engage in strenuous, planned physical activity)
• The ability to give informed consent

Exclusion criteria

• Currently taking a statin drug or NSAIDs
• Have a current peptic ulcer
• Have any renal impairment
• Have a known hypersensitivity to Acipimox
• Suffer from vertigo
• Smoker

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

2 participants in 2 patient groups, including a placebo group

Acipimox plus exercise training

Experimental group

Description:

The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for 6 weeks.

Treatment:

Dietary Supplement: Acipimox

Placebo plus exercise training

Placebo Comparator group

Description:

The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.

Treatment:

Dietary Supplement: Placebo